Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ipsen and Medicis have announced that the FDA has accepted the filing of Ipsen's biologics license application for Reloxin, its botulinum toxin type A, in aesthetic use in the US. This acceptance signifies the start of the review process of the dossier.
Subscribe to our email newsletter
In accordance with the agreement between the two parties, Medicis will pay Ipsen approximately $25 million and subject to approval of the biologics license application by the FDA, Medicis will pay to Ipsen a further $75 million and will commercialize Reloxin in the US.